TOOKAD®Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer

2013 ◽  
Vol 112 (6) ◽  
pp. 766-774 ◽  
Author(s):  
Abdel-Rahmène Azzouzi ◽  
Eric Barret ◽  
Caroline M. Moore ◽  
Arnaud Villers ◽  
Clare Allen ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Optimal Treatment ◽  
Treatment Conditions

Determination of Sarcosine Based on Magnetic Cross-linked Enzyme Aggregates for Diagnosis of Prostate Cancer

2021 ◽  
pp. 108039
Author(s):  
Qianqian Hu ◽  
Guoning Chen ◽  
Jili Han ◽  
Lu Wang ◽  
Xia Cui ◽  
...  
Keyword(s):  
Prostate Cancer

scholarly journals Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer

2021 ◽  
Vol 14 (3) ◽  
pp. 188
Author(s):  
Ines Katzschmann ◽  
Heike Marx ◽  
Klaus Kopka ◽  
Ute Hennrich
Keyword(s):  
Prostate Cancer ◽  
Quality Control ◽  
Radiochemical Purity ◽  
Control Method ◽  
Solid Phase ◽  
Hplc Method ◽  
Attractive Alternative ◽  
Chromatography Method ◽  
Pet Tracer

For the PET imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. [18F]PSMA-1007, a radiopharmaceutical labeled with fluorine-18, has excellent properties for the detection of prostate cancer. Essential for the human use of a radiotracer is its production and quality control under GMP-compliance. For this purpose, all analytical methods have to be validated. [18F]PSMA-1007 is easily radiosynthesized in a one-step procedure and isolated using solid phase extraction (SPE) cartridges followed by formulation of a buffered injection solution and for the determination of its chemical and radiochemical purity a robust, fast and reliable quality control method using radio-HPLC is necessary. After development and optimizations overcoming problems in reproducibility, the here described radio-HPLC method fulfills all acceptance criteria—for e.g., specificity, linearity, and accuracy—and is therefore well suited for the routine quality control of [18F]PSMA-1007 before release of the radiopharmaceutical. Recently a European Pharmacopeia monograph for [18F]PSMA-1007 was published suggesting a different radio-HPLC method for the determination of its chemical and radiochemical purity. Since the here described method has certain advantages, not least of all easier technical implementation, it can be an attractive alternative to the monograph method. The here described method was successfully validated on several radio-HPLC systems in our lab and used for the analysis of more than 60 batches of [18F]PSMA-1007. Using this method, the chemical and radiochemical purity of [18F]PSMA-1007 can routinely be evaluated assuring patient safety.

Is the determination of prostatic acid phosphatase still worthwhile in prostate cancer patients?

1997 ◽  
Vol 3 (2) ◽  
pp. 47-50
Author(s):  
Walter L Strohmaier ◽  
Andreas Zumbraegel ◽  
Lennart Koschella ◽  
K Horst Bichler
Keyword(s):  
Prostate Cancer ◽  
Acid Phosphatase ◽  
Cancer Patients ◽  
Prostatic Acid Phosphatase

Determination of cyclooxygenases and arachidonic acid metabolites in invasive human prostate cancer cells

1999 ◽  
Vol 59 (1-6) ◽  
pp. 13
Author(s):  
Kasem Nithipatikom ◽  
Christine Borcheid ◽  
Andre A. Kajdacsy-Balla ◽  
Sushma Kaul ◽  
Paul F. Lindholm ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Arachidonic Acid ◽  
Cancer Cells ◽  
Human Prostate ◽  
Human Prostate Cancer ◽  
Prostate Cancer Cells ◽  
Arachidonic Acid Metabolites ◽  
Acid Metabolites
Sign in / Sign up

Export Citation Format

Share Document